Table 1.
Baseline characteristics in advanced lung cancer patients treated with ICIs.
| Variables | CIP group (n = 87) | Control group (n = 87) | P-value |
|---|---|---|---|
| Age | |||
| Median (range) | 65 (18–85) | 62 (31–83) | 0.20 |
| <65, n (%) | 42 (48.3) | 52 (59.8) | 0.17 |
| ≥65, n (%) | 45 (51.7) | 35 (40.2) | |
| Gender, n (%) | 0.26 | ||
| Male | 73 (83.9) | 66 (75.9) | |
| Female | 14 (16.1) | 21 (24.1) | |
| Smoking status, n (%) | 0.76 | ||
| Current/former | 45 (51.7) | 42 (48.3) | |
| Never | 42 (48.3) | 45 (51.7) | |
| Preexisting lung diseases, n (%) | 15 (17.2) | 14 (16.1)) | 1 |
| Histologic type, n (%) | <0.001 | ||
| Squamous | 37 (42.5) | 13 (14.9) | |
| Adenocarcinoma | 22 (25.3) | 54 (62.1) | |
| NOS | 3 (3.4) | 3 (3.4) | |
| SCLC | 10 (11.5) | 9 (10.3) | |
| Others | 15 (17.2) | 8 (9.2) | |
| ECOG PS | 0.08 | ||
| 0–1 | 82 (94.3) | 74 (85.1) | |
| ≥2 | 5 (5.7) | 13 (14.9) | |
| Prior radiation, n (%) | 18 (20.7) | 9 (10.3) | 0.06 |
| EGFR/ALK mutation (initial biopsy/pre-TKI) | 6 (6.9) | 3 (3.4) | 0.28 |
| Treatment line, n (%) | |||
| 1 | 62 (71.3) | 70 (80.5) | 0.11 |
| ≥2 | 25 (28.7) | 17 (19.5) | |
| ICI type, n (%) | 1 | ||
| PD-1 | 82 (94.3) | 82 (94.3) | |
| PD-L1 | 5 (5.7) | 5 (5.7) | |
| Treatment data, n (%) | <0.001 | ||
| Monotherapy | 22 (25.3) | 3 (3.4) | |
| Combination therapy | 65 (74.7) | 84 (96.6) |
Bold values indicate p < 0.05; NOS, not otherwise specified; SCLC, small cell lung cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor gene; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitors; ICI, immune checkpoint inhibitors; PD-1, programmed cell death protein-1; PD-L1, programmed death ligand-1; CIP, checkpoint inhibitor-related pneumonitis.